Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr;15 Suppl 1(Suppl 1):S72-9.
doi: 10.1007/s10461-011-9894-1.

Pre-exposure prophylaxis and the promise of combination prevention approaches

Susan P Buchbinder  1 , Albert Liu
Affiliations

Pre-exposure prophylaxis and the promise of combination prevention approaches

Susan P Buchbinder et al. AIDS Behav. 2011 Apr.

Abstract

Pre-exposure prophylaxis (PrEP) for HIV prevention is a promising experimental approach currently being tested globally. A number of PrEP trials are evaluating the safety and effectiveness of PrEP in men who have sex with men (MSM) and other populations at risk for HIV, and results will be available from this first generation of efficacy trials over the next few years. Here we review the rationale for orally-administered antiretrovirals for prevention, and outline issues the first generation trials will address as well as questions that may be addressed in future studies. We also describe the rationale for combination prevention approaches that may combine PrEP with other prevention modalities as part of a larger prevention package.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study design of US CDC tenofovir (TDF) study
See this image and copyright information in PMC

References

    1. Grohskopf L, Gvetadze R, Pathak S, et al. Preliminary analysis of biomedical data from the phase II clinical safety trial of tenofovir disoproxil fumarate (TDF) for HIV-1 pre-exposure prophylaxis (PrEP) among U.S. men who have sex with men (MSM). XVIII international AIDS conference; Vienna, Austria 2010 [abstract FRLBC102].
    1. Mutua GN, Sanders EJ, Kamali A, et al. Safety and adherence to intermittent emtricitabine/tenofovir for HIV pre-exposure prophylaxis (PrEP) in Kenya and Uganda. XVIII international AIDS conference; Vienna, Austria 2010.
    1. Karim QA, Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–1174. doi: 10.1126/science.1193748. - DOI - PMC - PubMed
    1. Freedman DO. Clinical practice. Malaria prevention in short-term travelers. N Engl J Med. 2008;359(6):603–612. doi: 10.1056/NEJMcp0803572. - DOI - PubMed
    1. Panel on treatment of HIV-infected pregnant women and prevention of perinatal transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. May 24, 2010. p. 1–117. http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf. Accessed Sept 2010.

MeSH terms

Substances